Skip to main content Skip to section navigation Skip to footer
ProMIS Neurosciences, Inc.
  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Business Advisory Board
  • Our Science
  • Product Pipeline
    • Overview
    • Alzheimer’s Disease
    • ALS
    • Parkinson’s Disease
    • Posters & Publications
  • News & Media
    • Press Releases
    • Corporate Presentations
    • Events
    • In The News
    • Videos
    • Commentary
    • Podcasts
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Results
    • Stock Data
    • SEDAR
    • SEC Filings
    • Governance
  • Careers
  • Contact

In The News

News & Media

News & Media

  • Press Releases
  • Corporate Presentations
  • Events
  • In The News
  • Videos
  • Commentary
  • Podcasts
Dec 12, 2019

Getting on Target for Alzheimer’s

Dec 12, 2019

Biogen Reports Drug Effective in Slowing Alzheimer’s Disease: ‘A Milestone Achievement’

Dec 12, 2019

Episode 90: Biogen's big reveal, hot takes on Alzheimer's, & the science of one-eyed sheep

Nov 7, 2019

Financial Times – Alzheimer’s drug revival gives hope to millions — and investors

Nov 7, 2019

STAT – Biogen’s good news on aducanumab could ‘open the floodgates’ for Alzheimer’s drugs

Jun 13, 2019

The Big Biz Show – Interview with Dr. Elliot Goldstein

Jun 11, 2019

European Biopharmaceutical Review July 2019

May 28, 2019

Alzheimer’s Solution Shows Promise after Big Pharma’s Cure Fails

May 28, 2019

Ending Parkinson’s disease: The path is getting shorter

May 28, 2019

Alzheimer’s Disease is a ‘Double-Prion Disorder,’ Study Shows

rss_feed RSS
  • arrow_back
  • 1
  • 2
  • 3
  • 4
  • 5
  • arrow_forward
Facebook Linkedin Spotify Twitter
©2022 ProMIS Neurosciences, Inc. All Rights Reserved.
Disclaimer Sitemap Cookie Policy Privacy Policy